| Combination therapy strategy of tumor immune checkpoint inhibitor and its clinical application |
| Received:May 08, 2020 Revised:September 26, 2020 Click here to download the full text |
| Citation of this paper:LI Zhong-chen,REN Zheng-gang.Combination therapy strategy of tumor immune checkpoint inhibitor and its clinical application[J].Chinese Journal of Clinical Medicine,2020,27(6):909-916 |
| Hits: 2210 |
| Download times: 612 |
| Author Name | Affiliation | E-mail | | LI Zhong-chen | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Institute of Liver Cancer, Fudan University, Shanghai 200032, China | | | REN Zheng-gang | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Institute of Liver Cancer, Fudan University, Shanghai 200032, China | ren.zhenggang@zs-hospital.sh.cn |
|
| Abstract:The implementation of immune checkpoint inhibitions (ICIs) has improved the prognosis of multiple cancers. Anti-programmed cell death 1(PD-1)/anti-programmed cell death 1 ligand 1 (PD-L1) and anti-CTLA-4 monotherapy showed the limited efficacy in clinical studies and there are unmet needs for the development of new strategy of immunotherapy. Currently, combination therapy strategies including combination of different ICIs, chemotherapy, or anti-angiogenesis agents have increased the response rate of ICIs in multiple cancers. The development of the inhibitors of novel immune checkpoint such as lymphocyte activation gene-3(LAG-3), T cell immunoglobulin mucin-3(TIM-3), and T cell immunoglobulin and ITIM domain(TIGIT) will be expected for further improving the survival of refractory cancer patients or patients who are resistant to present ICIs. |
| keywords:immune checkpoint inhibitions cancer combination therapy |
| HTML View Full Text View/Add Comment Download reader |
|
|
|